Innovating Works

CARTHAGO

Financiado
Cartilaginous tissue regeneration by non viral gene therapy taking the hurdles...
Cartilaginous tissue regeneration by non viral gene therapy taking the hurdles towards efficient delivery Chronic low back pain due to intervertebral disc (IVD) degeneration and osteoarthritis (OA) worldwide impact human health and well-being due to pain and impaired mobility. Non-viral gene therapy has great promise as safe and preci... Chronic low back pain due to intervertebral disc (IVD) degeneration and osteoarthritis (OA) worldwide impact human health and well-being due to pain and impaired mobility. Non-viral gene therapy has great promise as safe and precision treatment to restore IVD and joint tissue health. However, the lack of accessibility of the affected cartilaginous tissues to drugs has inhibited progress in this field. We will finally fulfil the promise of non-viral gene therapy in these diseases. We will do this through educating 15 young researchers in 10 different countries in physics, quality by design (QbD), nucleic acid chemistry, nanomedicine, cartilage and IVD biology, ethics, entrepreneurship and academic transferable skills. This highly multidisciplinary team will exploit the potential of gene therapy in IVD and joint disease by taking a multi-faceted approach towards the delivery and activity of oligonucleotides and encoding nucleic acids (NA). Cell and tissue delivery will be achieved by nucleic acid modification, innovative nanocarriers and tissue targeting, supported by QbD. Ultrasound will for the first time be used to enhance NA tissue penetration and transfection, and to trigger local release from systemically administered endogenous albumin-NA conjugates. Imaging tools will be developed to monitor in vivo regeneration, saving numerous animal lives in the future. Moreover, we will set up an educational framework for embedding biomedical ethics in biomedical research and valorisation, providing a firm and sustainable basis for Responsible Research and Innovation for future biomedical science and technology. Participation of a patient organisation and a scientific organisation experienced in the dialogue with society, will ensure researchers at ease in communicating with different audiences. Hence CARTHAGO will deliver the agile scientists freely moving between sectors and firmly anchored in society, required to take science and innovation to the next level in Europe. ver más
31/08/2024
UMC UTRECHT
4M€
Duración del proyecto: 47 meses Fecha Inicio: 2020-09-02
Fecha Fin: 2024-08-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2024-08-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
MSCA-ITN-2020: Innovative Training Networks
Cerrada hace 4 años
Presupuesto El presupuesto total del proyecto asciende a 4M€
Líder del proyecto
UNIVERSITAIR MEDISCH CENTRUM UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5